Sagimet Biosciences Says FDA Cleared IND And Issued Study May Proceed Letter For Phase 3 Trial Of Denifanstat In Moderate To Severe Acne; Initiation On Track For 2H 2026

Sagimet Biosciences

Sagimet Biosciences

SGMT

0.00
Sagimet Biosciences Says FDA Cleared IND And Issued Study May Proceed Letter For Phase 3 Trial Of Denifanstat In Moderate To Severe Acne; Initiation On Track For 2H 2026
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.